Can nitric oxide-releasing hybrid drugs alleviate adverse cardiovascular risks?

Future Medicinal Chemistry

Volumn 5, Issue 4, 2013, Pages 381-383

  Bhardwaj, Atul ^a   Kaur, Jatinder ^a   Knaus, Edward E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

cardiovascular risk; COX; diabetes; endothelial dysfunction; inflammation; nitric oxide

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; INDOMETACIN; MEGLITINIDE; NATEGLINIDE; NITRIC OXIDE; PROSTAGLANDIN; REACTIVE OXYGEN METABOLITE; ROFECOXIB; VALDECOXIB;

ADVERSE OUTCOME; ARTHRITIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INFLAMMATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; STOMACH HEMORRHAGE; STOMACH IRRITATION; THROMBOSIS; VASODILATATION; WORLD HEALTH ORGANIZATION;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; DIABETES MELLITUS, TYPE 2; DRUG DISCOVERY; HUMANS; HYPOGLYCEMIC AGENTS; NITRIC OXIDE DONORS;

EID: 84875197981     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.23     Document Type: Note

References (21)

1. Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100, 1134-1146 (1999).
2. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in Type 2 diabetes mellitus: insights from mechanistic studies. Lancet 371, 1800-1809 (2008).
3. Bhattacharyya OK, Shah BR, Booth GL. Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines. CA Med. Assoc. J. 179, 920-926 (2008).
4. Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension 26, 869-879 (1995).
5. Toda N, Imamura T, Okamura T. Alteration of nitric oxide-mediated blood fow regulation in diabetes mellitus. Pharmacol. Therap. 127, 189-209 (2010).
6. Keeble JE, Moore PK. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-infammatory and related nitric oxide-donating drugs. Br. J. Pharmacol. 137(3), 295-310 (2002).
7. Butler AR, Williams DLH. The physiological role of nitric oxide. Chem. Soc. Rev. 22, 233-241 (1993).
8. Napoli C, Ignarro LJ. Nitric oxide-releasing drugs. Annu. Rev. Pharmacol. To xicol. 43, 97-123 (2003).
9. Virsaladze D, Kipiani V. Endothelial dysfunction in diabetic vasculopathy. Ann. Biochem. Res. Educ. 1, 44-48 (2001).
10. Rahman S, Rahman T, Ismail AA, Rashid AR. Diabetes associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes. Metab. 9, 767-780 (2007).
11. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 33, 1389-1394 (2010).
12. Cooper ME, Bonnet F, Oldfeld M, Jandeleit-Dahm K. Mechanisms of diabetic vasculopathy: an overview. Am. J. Hypertens. 14, 475-486 (2001).
13. Simmons DL, Botting RM, Hla T. Cyclooxygenase Isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 56, 387-437 (2004).
14. Blobaum AL, Marnett LJ. Structural and functional basis of cyclooxygenase inhibition. J. Med. Chem. 50, 1425-1441 (2007).
15. Fitzgerald GA. Coxibs and cardiovascular disease. N. Engl. J. Med. 351, 1709-1711 (2004).
16. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 116, 4-15 (2006).
17. Calderone V. An update on hybrid drugs in cardiovascular drug research. Expert Opin. Drug Discov. 3(12), 1397-1408 (2008).
18. Kaur J, Bhardwaj A, Huang Z et al. Synthesis and biological investigations of nitric oxide releasing nateglinide and meglitinide Type 2 antidiabetic prodrugs: in vivo antihyperglycemic activities and blood pressure lowering studies. J. Med. Chem. 55, 7883-7891 (2012).
19. 2NHOH) cyclooxygenase-2 pharmacophore: synthesis, molecular modeling, and biological evaluation as anti-infammatory agents. ChemMedChem 7, 62-67 (2012).
20. Bhardwaj A, Batchu SN, Kaur J, Huang Z, Seubert JM, Knaus EE. Cardiovascular properties of a nitric oxide releasing rofecoxib analog: benefcial antihypertensive activity and enhanced recovery in an ischemic reperfusion injury model. ChemMedChem 7, 1365-1368 (2012).
21. Chiroli V, Benedini F, Ongini E, Soldato PD. Nitric oxide-donating non-steroidal anti-infammatory drugs: the case of nitroderivatives of aspirin. Eur. J. Med. Chem. 38, 441-446 (2003).